NantHealth (NH) Stock Price, News & Analysis

Company Overview

NantHealth, Inc. (NASDAQ: NH) is a healthcare technology company focused on delivering precision medicine and data-driven solutions to healthcare providers, payers and pharmaceutical organizations. The company develops and markets integrated software platforms and molecular diagnostics designed to enable personalized treatment plans, improve patient outcomes and streamline clinical workflows. NantHealth’s core offerings include cloud-based clinical decision support systems, genomic sequencing services and real-time data analytics tools that combine clinical, molecular and imaging data.

Founded in 2007 by entrepreneur and physician Dr. Patrick Soon-Shiong, NantHealth has built a suite of products that leverage artificial intelligence and machine learning algorithms. Its flagship Clarify® Data Platform aggregates and normalizes diverse data types, while the GPS Cancer® program provides comprehensive genomic profiling to guide oncologists in selecting targeted therapies. The company also offers IoT-enabled digital health devices for remote monitoring and medication adherence, alongside telehealth solutions that facilitate virtual consultations and collaboration among multidisciplinary care teams.

Headquartered in Culver City, California, NantHealth operates laboratories and support centers in the United States and maintains strategic partnerships in Europe and the Asia-Pacific region. Its services are utilized by academic medical centers, community hospitals, specialty clinics and pharmaceutical firms seeking biomarker discovery, clinical trial enrichment and real-world evidence generation. By integrating precision diagnostics with cloud-based workflows, NantHealth aims to reduce variability in care delivery and accelerate research into novel therapies.

Under the leadership of founder and Executive Chairman Dr. Patrick Soon-Shiong and an experienced executive management team, NantHealth continues to expand its product portfolio and global footprint. The company invests in ongoing research and development to enhance its AI-driven analytics, refine its sequencing assays and extend its digital health capabilities. NantHealth’s mission is to transform healthcare through the convergence of cutting-edge technology, molecular science and real-world clinical data.

Key Stats

• Today's Range: $0.0110 to $0.0110
• 50-Day Range: $0.00 to $0.05
• 52-Week Range: $1.24 to $9.75
• Volume: 20 shs
• Average Volume: 38,073 shs
• Market Capitalization: $84.73 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NH Stock Analysis - Frequently Asked Questions

How have NH shares performed this year?

NantHealth's stock was trading at $0.0031 at the beginning of the year. Since then, NH shares have increased by 254.8% and is now trading at $0.0110.

How were NantHealth's earnings last quarter?

NantHealth, Inc. (NASDAQ:NH) announced its earnings results on Thursday, November, 4th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.02. The business had revenue of $14.36 million for the quarter, compared to analysts' expectations of $17.70 million.

When did NantHealth IPO?

NantHealth (NH) raised $91 million in an initial public offering (IPO) on Thursday, June 2nd 2016. The company issued 6,500,000 shares at a price of $12.50-$15.50 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and First Analysis Securities, Canaccord Genuity and FBR were co-managers.

How do I buy shares of NantHealth?

Shares of NH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NantHealth own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NantHealth investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), AT&T (T), Verizon Communications (VZ), AbbVie (ABBV), Gilead Sciences (GILD).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 7/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Data processing & preparation
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:NH
• Previous Symbol: NYSE:NH
• CIK: 1566469
• Web: www.nanthealth.com
• Phone: (855) 949-6268
• Fax: N/A
• Employees: 340
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($7.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$67.78 million
• Net Margins: -94.67%
• Pretax Margin: -95.06%
• Return on Equity: N/A
• Return on Assets: -39.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.64
• Quick Ratio: 0.64

Sales & Book Value

• Annual Sales: $67.68 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($30.72) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 7,703,000
• Free Float: 2,981,000
• Market Cap: $84.73 thousand
• Optionable: Not Optionable
• Beta: 1.82